Design, Synthesis and Cytotoxicity Evaluation of New 3, 5-Disubstituted-2- Thioxoimidazolidinones

Khaled R.A. Abdellatif^{a,b,*}, Mostafa M. Elbadawi^c, Mohammed T. Elsaady^d, Amer A. Abd El-Hafeez^{e,f}, Takashi Fujimura^e, Seiji Kawamoto^e and Ahmed I. Khodair^g

Abstract: *Background:* Some 2-thioxoimidazolidinones have been reported as anti-prostate and anti-breast cancer agents through their inhibitory activity on topoisomerase I that is considered as a potential chemotherapeutic target.

Objective: A new series of 3,5-disubstituted-2-thioxoimidazolidinone derivatives **10a- f** and their S-methyl analogs **11a-f** were designed, synthesized and evaluated for cytotoxicity against human prostate cancer cell line (PC-3), human breast cancer cell line (MCF-7) and non-cancerous human lung fibroblast cell line (WI-38).

Results and Method: While compounds 10a-f showed a broad range of activities against PC-3 and MCF-7 cell lines IC50 = 34.0 - 186.9 and 24.6 - 147.5 µM respectively), the S-methyl analogs 11a-f showed (IC50 = 22.7 - 198.5 and

 $188.2-16.9\mu M$ respectively) in comparison with 5-fluorouracil (IC50 =60.7 and $40.7~\mu M$ respectively). 11c (IC50 22.7 and 29.2 μM) and 11f (IC50 =28.7 and 16.9 μM) were the most potent among all compounds against both PC-3 and MCF-7 respectively with no cytotoxicity against WI-38.

Conclusion: The newly synthesized compounds showed good activity against PC-3 and MCF-7 cell lines in comparison with 5-fluorouracil. Compounds **11c** and **11f** bound with human topoisomerase I similar to its known inhibitors and significantly inhibited its DNA relaxation activity in a dose dependent manner which may rationalize their molecular mechanism as cytotoxic agents.

^aDepartment of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef 62514, Egypt;

^bPharmaceutical Sciences Department, Ibn Sina National College for Medical Studies, Jeddah 21418, Kingdom of Saudi Arabia:

^cDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt;

^dDepartment of Medicinal Chemistry, Beni-Suef University, Beni-Suef 62514, Egypt; ^eDepartment of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Higashi-Hiroshima, Japan;

^fPharmacology and experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt;

⁹Department of Organic Chemistry, Faculty of Science, Kafrelsheikh University, Kafrelsheikh, Egypt